Metastatik malign melanom: İnterferon alfa-2b ile dacarbazine kombinasyonu
Küçük Resim Yok
Tarih
1999
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Tek ajan olarak dacarbazine (DTIC) metastatik malign melanomlu (MMM) hastalarda standart tedavidir. Diğer antineoplastik ajanların tek veya kombine olarak DTIC'den daha iyi olduğuna ilişkin bulgu yoktur. Bu çalışmada, MMM tedavisinde DTIC le birlikte interferon alfa 2b'nin (IFN) kombine kullanımının etkinliğini değerlendirdik. MMM tanılı 25 hasta çalışmaya alındı. DTIC, 200 mg/m2 dozda, 5 gün süreyle, 28 günde bir, IFN alfa 2b 10x106 Ü haftada üç gün olarak uygulandı. 25 hastanın 7'sinde (1 tam yanıt [TY], 6 kısmi yanıt[KY]) objektif yanıt elde edildi (%28). Sağkalım analizinde progresyona kadar geçen süre medyan 6 aydı. Bu kombinasyon ve şema, MMM'lu hastalarda kabul edilebilir antitümör aktiviteye sahiptir.
Single agent dacarbazine (DTIC) is the standart therapy for patients with metastatic malignant melanoma (MMM). There is no evidence that any other antineoplastic agents, either alone or in combination is better than single agent DTIC. In this study, we evaluated efficacy of interferon alpha 2b (IFN) and DTIC combination therapy in management of MMM. Twenty-five patients with MMM were enrolled into the study. DTIC was administered at a dose of 200 mg/m2 for 5 days repeated every 28 days, plus IFN alpha 2b 10x106 U three times per week. Objective responses were seen in 7 of 25 patients (1 complete response [CR] and 6 partial responses [PRs]), for an objective response rate of 28%. Survival analysis showed that medyan time to progression was (TTP) 6 months. This combination and schedule has acceptable antitumor activity in patients with MMM.
Single agent dacarbazine (DTIC) is the standart therapy for patients with metastatic malignant melanoma (MMM). There is no evidence that any other antineoplastic agents, either alone or in combination is better than single agent DTIC. In this study, we evaluated efficacy of interferon alpha 2b (IFN) and DTIC combination therapy in management of MMM. Twenty-five patients with MMM were enrolled into the study. DTIC was administered at a dose of 200 mg/m2 for 5 days repeated every 28 days, plus IFN alpha 2b 10x106 U three times per week. Objective responses were seen in 7 of 25 patients (1 complete response [CR] and 6 partial responses [PRs]), for an objective response rate of 28%. Survival analysis showed that medyan time to progression was (TTP) 6 months. This combination and schedule has acceptable antitumor activity in patients with MMM.
Açıklama
Anahtar Kelimeler
Onkoloji
Kaynak
Türk Hematoloji Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
9
Sayı
3
